HC Wainwright & Co. Reiterates Buy on CASI Pharmaceuticals, Maintains $10 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Sean Lee reiterated a Buy rating on CASI Pharmaceuticals (NASDAQ:CASI) and maintained a $10 price target.
May 22, 2023 | 10:17 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Sean Lee reiterated a Buy rating on CASI Pharmaceuticals and maintained a $10 price target.
The reiteration of a Buy rating and maintenance of a $10 price target by HC Wainwright & Co. analyst Sean Lee indicates a positive outlook for CASI Pharmaceuticals. This news is likely to have a positive impact on the stock price in the short term as it shows confidence in the company's potential growth and performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100